135 related articles for article (PubMed ID: 28152224)
1. Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient.
Rahawi KW; Higgins KL; Noda C; Stultz JS
Pharmacotherapy; 2017 Apr; 37(4):e16-e20. PubMed ID: 28152224
[TBL] [Abstract][Full Text] [Related]
2. Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study.
Miranda S; Le Cam-Duchez V; Benichou J; Donnadieu N; Barbay V; Le Besnerais M; Delmas FX; Cuvelier A; Lévesque H; Benhamou Y; Armengol G
Thromb Res; 2017 Jul; 155():1-5. PubMed ID: 28460259
[TBL] [Abstract][Full Text] [Related]
3. Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
May CC; Cua S; Smetana KS; Powers CJ
World Neurosurg; 2022 Jan; 157():e357-e363. PubMed ID: 34655821
[TBL] [Abstract][Full Text] [Related]
4. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
Ramos-Esquivel A; Salazar-Sánchez L
Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
[TBL] [Abstract][Full Text] [Related]
5. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.
van Oosterom N; Winckel K; Barras M
J Thromb Thrombolysis; 2019 Oct; 48(3):387-393. PubMed ID: 30945098
[TBL] [Abstract][Full Text] [Related]
7. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Lee YR; Vega JA; Duong HN; Ballew A
Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
9. The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center.
Sacha GL; Greenlee KM; Ketz JM
J Thromb Thrombolysis; 2016 Nov; 42(4):479-85. PubMed ID: 27256341
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
11. Dosage of enoxaparin among obese and renal impairment patients.
Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
[TBL] [Abstract][Full Text] [Related]
12. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
13. Effect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels.
Peters BJ; Hofer M; Daniels CE; Winters JL
Am J Health Syst Pharm; 2018 Dec; 75(23):1883-1888. PubMed ID: 30463865
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
Stephenson ML; Serra AE; Neeper JM; Caballero DC; McNulty J
J Perinatol; 2016 Feb; 36(2):95-9. PubMed ID: 26658126
[TBL] [Abstract][Full Text] [Related]
15. Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level.
Mahe I; Gouin-Thibault I; Drouet L; Simoneau G; Di Castillo H; Siguret V; Bergmann JF; Pautas E
Drugs Aging; 2007; 24(1):63-71. PubMed ID: 17233548
[TBL] [Abstract][Full Text] [Related]
16. Residual Enoxaparin Activity, Anti-Xa Levels, and Concerns About the American Society of Regional Anesthesia and Pain Medicine Anticoagulation Guidelines.
Henshaw DS; Turner JD; Forest DJ; Thompson GR; Weller RS
Reg Anesth Pain Med; 2017; 42(4):432-436. PubMed ID: 28492441
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.
Thompson-Moore NR; Wanat MA; Putney DR; Liebl PH; Chandler WL; Muntz JE
Clin Appl Thromb Hemost; 2015 Sep; 21(6):513-20. PubMed ID: 25601898
[TBL] [Abstract][Full Text] [Related]
18. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
19. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
[TBL] [Abstract][Full Text] [Related]
20. Variability of plasma anti-Xa activities with different lots of enoxaparin.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
